7,500 Shares in Vera Therapeutics, Inc. (NASDAQ:VERA) Acquired by AlphaCentric Advisors LLC

AlphaCentric Advisors LLC bought a new position in shares of Vera Therapeutics, Inc. (NASDAQ:VERA) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 7,500 shares of the company’s stock, valued at approximately $332,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of VERA. Capstone Investment Advisors LLC bought a new stake in Vera Therapeutics during the 1st quarter worth approximately $248,000. FORA Capital LLC bought a new stake in Vera Therapeutics during the 1st quarter worth approximately $692,000. Jennison Associates LLC bought a new stake in Vera Therapeutics during the 1st quarter worth approximately $3,231,000. SG Americas Securities LLC increased its holdings in Vera Therapeutics by 54.9% during the 1st quarter. SG Americas Securities LLC now owns 11,941 shares of the company’s stock worth $515,000 after acquiring an additional 4,232 shares during the period. Finally, Swiss National Bank increased its holdings in Vera Therapeutics by 27.7% during the 1st quarter. Swiss National Bank now owns 62,200 shares of the company’s stock worth $2,682,000 after acquiring an additional 13,500 shares during the period. Institutional investors own 99.21% of the company’s stock.

Insider Buying and Selling at Vera Therapeutics

In other Vera Therapeutics news, Director Beth C. Seidenberg sold 1,177 shares of the stock in a transaction on Wednesday, September 18th. The shares were sold at an average price of $42.01, for a total transaction of $49,445.77. Following the completion of the sale, the director now owns 160,376 shares of the company’s stock, valued at $6,737,395.76. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other news, CEO Marshall Fordyce sold 15,625 shares of the firm’s stock in a transaction dated Wednesday, September 11th. The shares were sold at an average price of $37.50, for a total value of $585,937.50. Following the completion of the sale, the chief executive officer now directly owns 307,972 shares of the company’s stock, valued at approximately $11,548,950. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Beth C. Seidenberg sold 1,177 shares of the firm’s stock in a transaction dated Wednesday, September 18th. The stock was sold at an average price of $42.01, for a total transaction of $49,445.77. Following the completion of the sale, the director now directly owns 160,376 shares of the company’s stock, valued at approximately $6,737,395.76. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 104,398 shares of company stock valued at $4,376,163 in the last quarter. Company insiders own 21.70% of the company’s stock.

Vera Therapeutics Stock Performance

VERA stock opened at $45.17 on Tuesday. The company has a quick ratio of 21.43, a current ratio of 21.43 and a debt-to-equity ratio of 0.15. Vera Therapeutics, Inc. has a 52 week low of $9.88 and a 52 week high of $50.78. The firm’s fifty day moving average is $40.65 and its 200 day moving average is $38.90.

Vera Therapeutics (NASDAQ:VERA) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.56) by ($0.06). On average, sell-side analysts forecast that Vera Therapeutics, Inc. will post -2.57 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently commented on VERA. Guggenheim increased their price target on shares of Vera Therapeutics from $56.00 to $64.00 and gave the stock a “buy” rating in a report on Monday, October 28th. Cantor Fitzgerald reissued an “overweight” rating and issued a $107.00 price target on shares of Vera Therapeutics in a report on Tuesday, October 1st. Scotiabank began coverage on shares of Vera Therapeutics in a report on Wednesday, October 16th. They issued a “sector outperform” rating and a $60.00 price target on the stock. Evercore ISI raised shares of Vera Therapeutics to a “strong-buy” rating in a report on Monday, September 16th. Finally, JPMorgan Chase & Co. increased their price target on shares of Vera Therapeutics from $62.00 to $72.00 and gave the stock an “overweight” rating in a report on Tuesday, September 3rd. One research analyst has rated the stock with a hold rating, seven have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $53.56.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.